Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KH617 +/- Temozolomide in Recurrent Glioblastoma
NCT07138001Phase 2Not yet recruiting
- Sponsor
- Sichuan Honghe Biotechnology Co., Ltd.
- Start
- Aug 2025
- Primary completion
- Sep 2027
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of KH617 in glioblastoma (GBM) (3 arms), sponsored by Sichuan Honghe Biotechnology Co., Ltd. Primary endpoints: Objective Response Rate at 54 weeks, Progression-Free Survival at 6 months and 1 more. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
KH617
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT07138001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07138001.